Gabapentin Tablet
Product Images NDC 60760-517

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 517 60)

This packaging label is for Gabapentin Tablets USP 800 mg, with a quantity of 60 tablets. The label includes the NDC number 60760-517-60 and indicates it is manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label also states 'Use As Directed' and provides storage instructions to keep at controlled room temperature (15°-30°C). RX only.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over eight weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period for patients receiving placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period, showing pain score trends decreasing more in the Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) doses in two separate studies. Study 1 shows 12% responders on placebo and 29% on 3600 mg GBP, while Study 2 shows 14% responders on placebo and 32% and 34% responders on 1800 mg and 2400 mg GBP, respectively. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

A mathematical formula for calculating creatinine clearance (CLCr) is shown, incorporating variables such as age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing a cyclohexane ring attached to an aminomethyl group and a carboxymethyl group, representing its molecular composition as depicted in the diagram.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference on the y-axis against daily gabapentin dose in milligrams on the x-axis. The graph compares results from three studies labeled a, b, and c, with data points plotted for doses 600, 900, 1200, and 1800 mg, illustrating variation in differences by study and dose.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.